April 2024 tender notification

Pharmac - Te Pātaka Whaioranga is pleased to provide the latest tender results.

Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2022/23 Invitation to Tender, dated 31 October 2022, and the 2023/24 Invitation to Tender, dated 31 October 2023. 

Some of the Pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of Pharmaceuticals that are subject to such contracts should continue to supply their Pharmaceutical under those contracts. Pharmac will continue to subsidise those Pharmaceuticals accordingly until such time as those Pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:

  • For new listings, by 4pm on 12 May 2024 or the fifth of the month prior to listing, whichever is earlier
  • For price changes, by 4pm on the twelfth of the month prior to the date of subsidy change

Pharmac cannot list a product (and Pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website.

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link). Pharmacodes and CTPP codes must be provided to Pharmac by the fifth (5th) of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). Pharmac cannot list a product (and Pharmacies cannot claim) without the correct Pharmacode.

2022/23 Tender – Principal Supply Status applies until 30 June 2026

Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule

The decisions were as follows:

1. Tenders awarded to pharmaceuticals where at least one other brand is listed.

Chemical name Presentation;
Pack size and type
Current pack price New pack price Principal Supply brand
(Supplier)
Listing date Principal Supply date Brand (Supplier) affected by delisting
Teriflunomide Tab 14mg; 28 tablet blister pack $659.90 $263.96 Teriflunomide Sandoz (Sandoz) 1 November 2024 1 April 2025 Aubagio (Sanofi-Aventi)

Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.

2. Tenders awarded to pharmaceuticals where at least one other brand is listed.

Chemical name Presentation;
Pack size and type
Current pack price New pack price Principal Supply brand
(Supplier)
DV limit Listing date Principal Supply date Brand (Supplier) affected by delisting
Teriflunomide Tab 14mg; 28 tablet blister pack $659.90 $263.96 Teriflunomide Sandoz (Sandoz) 5% 1 November 2024 1 April 2025 Aubagio (Sanofi-Aventi)

2023/24 Tender – Principal Supply Status applies until 30 June 2027

Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule

The decisions were as follows:

3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

Chemical name Presentation;
Pack size and type
Current pack price New pack price Principal Supply brand
(Supplier)
Date of subsidy change Principal Supply date
Aprepitant Cap 2 x 80 mg and 1 x 125 mg; 3 capsule blister pack $30.00 $21.90 Emend (MSD) 1 August 2024 1 January 2025
Perindopril Tab 2 mg; 30 tablet blister pack $1.58 $1.79 Coversyl (Servier) 1 July 2024 1 December 2024
Perindopril Tab 4 mg; 30 tablet blister pack $2.95 $2.44 Coversyl (Servier) 1 July 2024 1 December 2024
Perindopril Tab 8 mg; 30 tablet blister pack $5.02 $3.94 Coversyl (Servier) 1 July 2024 1 December 2024
Sodium hyaluronate [hyaluronic acid] Eye drops 1 mg per ml; 10 ml bottle OP $13.85 $13.58 Hylo-Fresh (AFT) 1 July 2024 1 December 2024

4. Tenders awarded to pharmaceuticals where at least one other brand is listed.

Chemical name Presentation;
Pack size and type
Current pack price New pack price Principal Supply brand
(Supplier)
Listing date Principal Supply date Brand (Supplier) affected by delisting
Acetylcysteine Inj 200 mg per ml, 10ml ampoule; 10 ampoule pack $52.88 $42.99 DBL Acetylcysteine (Pfizer) 1 November 2024 1 April 2025 Martindale Pharma (Max Health)
Bimatoprost Eye drops 0.03%, 3ml dropper bottle OP $5.95 $5.15 Lumigan (AbbVie) 1 August 2024 1 January 2025 Bimatoprost Multichem (Multichem)

Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.

5. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

Chemical name Presentation;
Pack size and type
Pack price Principal Supply brand
(Supplier)
DV Limit Date of subsidy change Principal Supply date
Adenosine Inj 3mg per ml, 10 ml vial; 5 vial pack $100.00 Adenosine Baxter (Baxter) 5% 1 July 2024 1 December 2024
Levosimendan Inj 2.5 mg per ml, 5 ml vial; 1 vial pack $509.60 Simdax (Max Health) 5% 1 June 2024 1 November 2024

 6. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

Chemical name Presentation;
Pack size and type
Current pack price New pack price Principal Supply brand
(Supplier)
DV Limit Date of subsidy change Principal Supply date
Aprepitant Cap 2 x 80 mg and 1 x 125 mg; 3 cap pack $30.00 $21.90 Emend (MSD) 5% 1 August 2024 1 January 2025
Perindopril Tab 2 mg; 30 tablet blister pack $1.58 $1.79 Coversyl (Servier) 5% 1 July 2024 1 December 2024
Perindopril Tab 4 mg; 30 tablet blister pack $2.95 $2.44 Coversyl (Servier) 5% 1 July 2024 1 December 2024
Perindopril Tab 8 mg; 30 tablet blister pack $5.02 $3.94 Coversyl (Servier) 5% 1 July 2024 1 December 2024
Sodium hyaluronate [hyaluronic acid] Eye drops 1 mg per ml; 10 ml bottle $13.85 $13.58 Hylo-Fresh (AFT) 5% 1 July 2024 1 December 2024

7. Tenders awarded to pharmaceuticals where at least one other brand is listed.

Chemical name Presentation;
Pack size and type
Current pack price New pack price Principal Supply brand
(Supplier)
DV Limit Listing date Principal Supply date Brand (Supplier) affected by delisting
Acetylcysteine Inj 200 mg per ml, 10ml ampoule; 10 ampoule pack $52.88 $42.99 DBL Acetylcysteine (Pfizer) 5% 1 November 2024 1 April 2025 Martindale Pharma (Max Health)
Adenosine Inj 3 mg per ml, 2 ml vial; 5 vial pack $62.73 $34.50 Adsine (Baxter) 5% 1 July 2024 1 December 2024 Adenocor (Sanofi)
Bimatoprost Eye drops 0.03%, 3ml dropper bottle $5.95 $5.15 Lumigan (AbbVie) 5% 1 August 2024 1 January 2025 Bimatoprost Multichem (Multichem)
Cefepime Inj 1g vial; 1 vial pack $35.00 $3.19 Cefepime-AFT (AFT) 5% 1 July 2024 1 December 2024 Cefepime Kabi (Fresenius Kabi)
Cefepime Inj 2g vial; 1 vial pack $55.00 $4.99 Cefepime-AFT (AFT) 5% 1 July 2024 1 December 2024 Cefepime Kabi (Fresenius Kabi)
Cisplatin1 Inj 1 mg per ml, 100 ml vial; 1 vial pack $29.66 $18.90 Cisplatin Accord (Accord) 5% 1 July 2024 1 December 2024 DBL Cisplatin (Pfizer)

 1The price and subsidy of cispatin (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be listed at the above prices from 1 December 2024. The subsidy of cisplatin inj 1 mg for ECP (Baxter) will be reduced from $0.31 per 1 mg to $0.19 per 1 mg from 1 July 2024 in Section B of the Pharmaceutical Schedule. 

Tender declines – Products where no tender is to be awarded for Principal Supply Status

Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2023/24 Invitation to Tender, dated 31 October 2023.

Chemical Name Line Item
Aprepitant (current access) Cap 40 mg
Aprepitant (current access) Cap 80 mg
Aprepitant (current access) Cap 125 mg
Aprepitant (current access) Cab 165 mg
Aprepitant (widened access) Cap 2 x 80 mg and 1 x 125 mg
Aprepitant (widened access) Cap 40 mg
Aprepitant (widened access) Cap 80 mg
Aprepitant (widened access) Cap 125 mg
Aprepitant (widened access) Cab 165 mg
Carbomer Ophthalmic gel 0.3%
Cisplatin Inj 1 mg per ml, 50 ml
Doxorubicin Inj 10 mg
Doxorubicin Inj 50 mg
Doxorubicin Inj 100 mg
Doxorubicin Inj 200 mg
Morphine Tab immediate-release 10 mg
Morphine Tab immediate-release 20 mg
Norethisterone Tab 350 mcg
Octreotide Inj 50 mcg per ml, 1 ml
Octreotide Inj 100 mcg per ml, 1 ml
Octreotide Inj 500 mcg per ml, 1 ml
Pamidronate disodium Inj 3 mg per ml, 10 ml
Pamidronate disodium Inj 6 mg per ml, 10 ml
Pamidronate disodium Inj 9 mg per ml, 10 ml
Pancreatic enzyme Cap 150 mg
Pancreatic enzyme Cap 300 mg
Paracetamol Inj 10 mg per ml, 100 ml
Timolol Eye drops 0.25%, gel forming
Timolol Eye drops 0.5%, gel forming
Tramadol hydrochloride Oral soln 10 mg per ml

For products included in the 2021/22, 2022/23 and 2023/24 Invitation to Tender where no announcement has yet been made, a decision is still pending subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.